The share price of the company (TXMD) was down -2.48%, with a high of 5.95 during the day and the volume of TherapeuticsMD, Inc. shares traded was 5128192.
The company has mean EPS estimate of -0.11 reported by 7 number of analyst for the quarter ending Feb 23, 2017- Feb 27, 2017. The average 12-month price objective among analysts that have updated their coverage on the stock in the previous year is $19.40. Zacks Investment Research upgraded TherapeuticsMD from a "sell" rating to a "hold" rating in a report on Tuesday, January 24th.
TherapeuticsMD Inc (NYSEMKT:TXMD)'s stock had its "overweight" rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research report issued on Monday.
TherapeuticsMD, Inc. had its "buy" rating reiterated by analysts at Stifel Nicolaus. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company's stock. The average numbers of shares are traded in a security per day, during the recent 3-month period.
Rusia prohíbe a los Testigos de Jehová
La organización internacional de los Testigos de Jehová , que cuenta con ocho millones de seguidores a nivel mundial, tiene 175 mil seguidores en Rusia .
TherapeuticsMD, Inc. (TXMD) closed -26.36% below its 200-day moving average and is -24.78% below another chart threshold, its 50-day moving average. Tracking the stock price in relation to moving averages as well as highs and lows for the year might assist with evaluating future stock performance. The stock has relative volume of 1.91.
TherapeuticsMD (NYSEMKT:TXMD) last issued its earnings results on Thursday, February 23rd. The stock lost -6.53% in total of its share price. (TXMD). These ratios are important while doing valuation of the company or the shares of the company. The firm's revenue for the quarter was down 20.2% compared to the same quarter a year ago. A month ago, analyst EPS consensus estimated earnings of US$-0.12 per share.
If you look at the company's income statement over the past years, you will see that the company is constantly posting gross profit: In 2014, TXMD earned gross profit of 11.35 Million, in 2015 15.64 Million gross profit, while in 2016 TherapeuticsMD, Inc.
Analysts' mean recommendation for TherapeuticsMD, Inc.
Fox stock holds steady following O'Reilly firing
Due to a confidentiality agreement, 21st Century Fox and O'Reilly's representatives would not acknowledge the payout. As we mentioned earlier, Bill O'Reilly is leaving this chair and this network after more than 20 years.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Markets Daily and is owned by of Markets Daily. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/04/16/therapeuticsmds-txmd-buy-rating-reiterated-at-oppenheimer-holdings-inc-updated.html.
Several institutional investors have recently added to or reduced their stakes in TXMD.
07/08/2016 - TherapeuticsMD, Inc. had its "buy" rating reiterated by analysts at Noble Financial. Buy rating has been given by 4 analysts to the company stock whereas 1 analyst given UNDERPERFORM rating to stock and 19 analysts given HOLD rating. State Street Corp boosted its position in TherapeuticsMD by 9.1% in the fourth quarter. There is no concrete way to calculate a price target. BlackRock Investment Management LLC boosted its position in shares of TherapeuticsMD by 1.3% in the third quarter. They now have a United States dollars 7 price target on the stock. Finally, Aperio Group LLC bought a new position in shares of TherapeuticsMD during the third quarter worth $164,000.
06/17/2014 - JMP Securities began new coverage on TherapeuticsMD, Inc. giving the company a " rating. The Company's segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products.
Officers Involved In United Flight Passenger Removal Placed On Administrative Leave
But other passengers on the plane can be heard arguing with authorities over Dao's treatment as the horror unfolds. United CEO Oscar Munoz's non-apology for "having to re-accommodate " the passengers didn't help much either.